Europe Fibrotic Diseases Treatment Market
Taille du marché en milliards USD
TCAC : %
Période de prévision |
2025 –2032 |
Taille du marché (année de référence) |
USD 1.37 Billion |
Taille du marché (année de prévision) |
USD 2.29 Billion |
TCAC |
|
Principaux acteurs du marché |
>Segmentation du marché du traitement des maladies fibrotiques en Europe, par traitement (médicaments, transplantation d'organes, oxygénothérapie et autres), application (fibrose pulmonaire idiopathique, cirrhose hépatique, fibrose rénale, fibrose cutanée et autres), utilisateur final (hôpitaux, cliniques spécialisées, instituts universitaires et de recherche et autres), canal de distribution (pharmacie hospitalière, pharmacie de détail et autres) - Tendances et prévisions du secteur jusqu'en 2031
Analyse du marché du traitement des maladies fibrotiques
Le marché européen du traitement des maladies fibrotiques devrait connaître une croissance significative dans les années à venir. Des facteurs tels que la prévalence croissante des maladies fibrotiques, la sensibilisation croissante aux options de traitement et les progrès de la technologie médicale sont à l'origine de cette croissance. L'infrastructure de santé bien établie de la région et son environnement réglementaire favorable contribuent également à l'expansion du marché. En outre, la croissance de la population âgée en Europe, plus sujette aux maladies fibrotiques, devrait alimenter la croissance du marché. L'adoption croissante de nouvelles thérapies et de nouveaux produits biologiques pour les maladies fibrotiques est une autre tendance clé dans la région.
Taille du marché du traitement des maladies fibrotiques
La taille du marché européen du traitement des maladies fibrotiques était évaluée à 6,18 milliards USD en 2023 et devrait atteindre 11,80 milliards USD d'ici 2031, avec un TCAC de 8,42 % au cours de la période de prévision de 2024 à 2031. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.
Portée du rapport et segmentation du marché
Rapport métrique |
Détails |
Période de prévision |
2024 à 2031 |
Année de base |
2023 |
Années historiques |
2022 (personnalisable pour 2016-2021) |
Unités quantitatives |
Chiffre d'affaires en milliards USD, volumes en unités, prix en USD |
Segments couverts |
Traitement (médicaments, transplantation d'organes , oxygénothérapie et autres), application (fibrose pulmonaire idiopathique, cirrhose hépatique, fibrose rénale, fibrose cutanée et autres), utilisateur final (hôpitaux, cliniques spécialisées, instituts universitaires et de recherche et autres), canal de distribution (pharmacie hospitalière, pharmacie de détail et autres) |
Pays couverts |
Allemagne, France, Royaume-Uni, Pays-Bas, Suisse, Belgique, Russie, Italie, Espagne, Turquie et reste de l'Europe |
Acteurs du marché couverts |
Boehringer Ingelheim International GmbH (Allemagne), AbbVie Inc. (États-Unis), Redx Pharma Plc (Royaume-Uni), Bristol-Myers Squibb Company (États-Unis), Gilead Sciences, Inc. (États-Unis), KITHER BIOTECH SRL (Italie), Verona Pharma plc (Royaume-Uni), Intercept Pharmaceuticals, Inc. (États-Unis), Pharmaxis Ltd. (Australie), Teva Pharmaceutical Industries Ltd. (Israël), Sandoz International GmbH (Autriche) |
Opportunités de marché |
|
Fibrotic Diseases Treatment Market Definition
Fibrotic diseases treatment refers to the medical interventions and therapies aimed at managing and treating conditions characterized by the development of excessive fibrous connective tissue, or fibrosis, in organs and tissues. Fibrosis is a common feature of many chronic diseases and can lead to organ dysfunction and failure. Treatment strategies for fibrotic diseases typically focus on reducing inflammation, slowing down or halting the progression of fibrosis, and managing symptoms to improve quality of life.
Fibrotic Diseases Treatment Market Dynamics
Drivers
- Increasing Prevalence of Fibrotic Diseases
The prevalence of fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF) and liver fibrosis, is on the rise, primarily due to factors such as aging populations and the increasing incidence of lifestyle-related diseases. As people live longer, the likelihood of developing fibrotic diseases increases, driving the demand for effective treatments and boosting market growth. Additionally, lifestyle factors such as smoking, obesity, and poor diet contribute to the development of fibrotic diseases, further increasing the prevalence and driving market growth.
- Advancements in Treatment Technologies
Technological advancements in the field of fibrotic diseases treatment have revolutionized the way these conditions are managed. Novel therapies and biologics offer more targeted and effective treatments, improving patient outcomes and quality of life. These advancements have led to a shift towards personalized medicine, where treatments are tailored to individual patients based on their specific needs and genetic makeup. This has significantly improved the efficacy of treatments and is a major driver for market growth.
- Rising Awareness and Diagnosis Rates
Increasing awareness about fibrotic diseases among both healthcare professionals and the general public has led to improved diagnosis rates and early detection. This has enabled patients to receive timely treatment, leading to better outcomes and driving market growth. Improved diagnostic capabilities, such as advanced imaging techniques and biomarker tests, have also contributed to the early detection of fibrotic diseases. As awareness continues to grow and diagnostic methods improve, more patients are expected to seek treatment, further driving market growth.
Opportunities
- Growing Healthcare Expenditure
Countries with aging populations are witnessing a rise in healthcare spending, particularly on advanced treatments for chronic conditions such as fibrotic diseases. This increase in expenditure is driven by the need to provide high-quality care to an aging population, as well as advancements in medical technology that offer more effective treatment options. As healthcare expenditure continues to grow, it is expected to drive market growth for fibrotic disease treatments, providing companies with opportunities to expand their market presence.
- Supportive Government Initiatives
Governments across Europe are implementing policies to enhance healthcare delivery systems and ensure that patients have access to high-quality care. These initiatives include investments in healthcare infrastructure, increased funding for research and development, and efforts to reduce barriers to accessing healthcare services. As a result, the market for fibrotic disease treatments is expected to benefit from these supportive government initiatives, providing companies with opportunities to expand their market reach and develop new treatment options.
Restraints/Challenges
- Side Effects of Treatment
Many existing treatments for fibrotic diseases, such as steroids and immunosuppressants, can cause adverse effects such as weight gain, mood changes, and increased susceptibility to infections. These side effects can lead to patient discomfort and non-compliance with treatment regimens, ultimately affecting the market for fibrotic disease treatments. The potential side effects of current treatments for fibrotic diseases can be a significant limitation to their use and can impact market growth.
- High Treatment Costs
The cost of medications, medical procedures, and hospitalization for fibrotic diseases can be substantial, placing a financial burden on patients and healthcare systems. This high cost can limit access to treatment for many patients, particularly those in developing countries or without adequate insurance coverage. The high cost of treatment for fibrotic diseases is a major restraint for market growth, particularly in countries with limited healthcare budgets.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Fibrotic Diseases Treatment Market Scope
The fibrotic diseases treatment market is categorized into four notable segments based on treatment, application, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Medication
- Organ Transplantation
- Oxygen Therapy
- Others
Application
- Idiopathic pulmonary fibrosis
- Hepatic cirrhosis
- Renal fibrosis
- Cutaneous fibrosis
- Others
End User
- Government organization
- Hospitals
- Academic and research institutes
- Others
Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- Others
Europe Fibrotic Diseases Treatment Market Regional Analysis
The market is analyzed and market size insights and trends are provided by country, treatment, application, end user, and distribution channel as referenced above.
The countries covered in the market are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, and rest of Europe.
Germany is expected to dominate and show significant growth in the market due to advancements in technology within developing regions. The country's strong position is bolstered by its robust healthcare infrastructure and a focus on innovation, particularly in fibrotic diseases. Germany's proactive approach to research and development, coupled with a favorable regulatory environment, positions it as a key player in advancing treatment options for fibrotic diseases across Europe.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Fibrotic Diseases Treatment Market Share
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Some of the major players operating in the market are:
- Boehringer Ingelheim International GmbH (Germany)
- AbbVie Inc. (U.S.)
- Redx Pharma Plc (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- Gilead Sciences, Inc. (U.S.)
- KITHER BIOTECH S.R.L. (Italy)
- Verona Pharma plc (U.K.)
- Intercept Pharmaceuticals, Inc. (États-Unis)
- Pharmaxis Ltd. (Australie)
- Teva Pharmaceutical Industries Ltd. (Israël)
- Sandoz International GmbH (Autriche)
Dernières évolutions sur le marché du traitement des maladies fibrotiques
- En mai 2023, Boehringer Ingelheim a annoncé le lancement du développement clinique de son premier anticorps inhibiteur de l'IL-11, le BI 765423. L'étude de phase 1 (NCT05658107) vise à évaluer l'innocuité, la tolérance et la pharmacocinétique du médicament chez des volontaires sains. Des études précliniques ont montré que ce médicament anti-IL-11 a le potentiel d'inhiber et même d'inverser la fibrose dans diverses maladies fibrotiques
- En mai 2023, Cumberland Pharmaceuticals Inc. a révélé que la FDA avait approuvé une demande de nouveau médicament expérimental (IND) pour une recherche de phase II impliquant des patients atteints de fibrose pulmonaire idiopathique (FPI), qui est la forme la plus répandue de maladie pulmonaire interstitielle fibrosante progressive.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE FIBROTIC DISEASE TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
5 EUROPE FIBROTIC DISEASES TREATMENT MARKET, REGULATIONS
5.1 NORTH AMERICA
5.1.1 U.S.
5.1.2 CANADA
5.2 EUROPE
5.2.1 EUROPEAN UNION (EMA - EUROPEAN MEDICINES AGENCY)
5.2.2 GERMANY (FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES - BFARM)
5.2.3 UNITED KINGDOM (MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY - MHRA)
5.3 ASIA-PACIFIC
5.3.1 JAPAN (PMDA - PHARMACEUTICALS AND MEDICAL DEVICES AGENCY)
5.3.2 CHINA (NMPA - NATIONAL MEDICAL PRODUCTS ADMINISTRATION)
5.3.3 AUSTRALIA (TGA - THERAPEUTIC GOODS ADMINISTRATION)
5.4 LATIN AMERICA
5.4.1 BRAZIL (ANVISA - BRAZILIAN HEALTH REGULATORY AGENCY)
5.4.2 ARGENTINA (ADMINISTRACIÓN NACIONAL DE MEDICAMENTOS, ALIMENTOS Y TECNOLOGÍA MÉDICA - ANMAT)
5.5 MIDDLE EAST AND AFRICA (MEA)
5.5.1 UNITED ARAB EMIRATES (UAE - MINISTRY OF HEALTH AND PREVENTION)
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF FIBROTIC DISEASES
6.1.2 INCREASE IN THE NUMBER OF PEOPLE SMOKING CIGARETTES
6.1.3 TECHNOLOGICAL ADVANCEMENT IN THE TREATMENT OF FIBROSIS DISEASES
6.1.4 AWARENESS AND EARLY DIAGNOSIS INITIATIVES
6.2 RESTRAINTS
6.2.1 HIGH COST OF MEDICATION AND TREATMENTS
6.2.2 LACK OF EFFECTIVE BIOMARKERS AND DIAGNOSTIC TOOLS FOR EARLY DETECTION AND MONITORING OF FIBROTIC DISEASES
6.3 OPPORTUNITIES
6.3.1 RISING RESEARCH AND DEVELOPMENT ACTIVITIES
6.3.2 ADVANCEMENTS IN PIPELINE DRUG DEVELOPMENTS
6.3.3 INCREASING STRATEGIC COLLABORATIONS AND PARTNERSHIPS
6.4 CHALLENGES
6.4.1 THE COMPLEX AND MULTIFACTORIAL NATURE OF FIBROTIC DISEASES.
6.4.2 HIGH RATE OF FAILURE IN CLINICAL TRIALS FOR FIBROTIC DISEASES,
7 EUROPE FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT
7.1 OVERVIEW
7.2 MEDICATION
7.2.1 MEDICATION, BY TREATMENT
7.2.2 MEDICATION, BY DISTRIBUTION CHANNEL
7.3 ORGAN TRANSPLANT
7.4 OXYGEN THERAPY
7.5 OTHERS
8 EUROPE FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 IDIOPATHIC PULMONARY FIBROSIS
8.3 HEPATIC CIRRHOSIS
8.4 RENAL FIBROSIS
8.5 CUTANEOUS FIBROSIS
8.6 OTHERS
9 EUROPE FIBROTIC DISEASE TREATMENT MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 SPECIALTY CLINICS
9.4 ACADEMIC AND RESEARCH INSTITUTES
9.5 OTHERS
10 EUROPE FIBROTIC DISEASE TREATMENT MARKET, BY REGION
10.1 EUROPE
11 EUROPE FIBROTIC DISEASE TREATMENT MARKET, COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: EUROPE
12 SWOT ANALYSIS
13 COMPANY PROFILE
13.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 COMPANY SHARE ANALYSIS
13.1.4 PRODUCT PORTFOLIO
13.1.5 RECENT DEVELOPMENTS
13.2 GENENTECH, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)
13.2.1 COMPANY SNAPSHOT
13.2.2 COMPANY SHARE ANALYSIS
13.2.3 PRODUCT PORTFOLIO
13.2.4 RECENT DEVELOPMENTS
13.3 TEVA PHARMACEUTICAL INDUSTRIES LTD.
13.3.1 COMPANY SNAPSHOT
13.3.2 REVENUE ANALYSIS
13.3.3 COMPANY SHARE ANALYSIS
13.3.4 PRODUCT PORTFOLIO
13.3.5 RECENT DEVELOPMENTS
13.4 SANDOZ INTERNATIONAL GMBH
13.4.1 COMPANY SNAPSHOT
13.4.2 COMPANY SHARE ANALYSIS
13.4.3 PRODUCT PORTFOLIO
13.4.4 RECENT DEVELOPMENTS
13.5 ACCORD HEALTHCARE
13.5.1 COMPANY SNAPSHOT
13.5.2 COMPANY SHARE ANALYSIS
13.5.3 PRODUCT PORTFOLIO
13.5.4 RECENT DEVELOPMENTS
13.6 ABBVIE INC.
13.6.1 COMPANY SNAPSHOT
13.6.2 REVENUE ANALYSIS
13.6.3 PRODUCT PORTFOLIO
13.6.4 RECENT DEVELOPMENTS
13.7 BRISTOL-MYERS SQUIBB COMPANY.
13.7.1 COMPANY SNAPSHOT
13.7.2 REVENUE ANALYSIS
13.7.3 PRODUCT PORTFOLIO
13.7.4 RECENT DEVELOPMENTS
13.8 BIOMX.
13.8.1 COMPANY SNAPSHOT
13.8.2 PRODUCT PORTFOLIO
13.8.3 RECENT DEVELOPMENTS
13.9 INTERCEPT PHARMACEUTICALS, INC.
13.9.1 COMPANY SNAPSHOT
13.9.2 REVENUE ANALYSIS
13.9.3 PRODUCT PORTFOLIO
13.9.4 RECENT DEVELOPMENTS
13.1 KITHER BIOTECH S.R.L.
13.10.1 COMPANY SNAPSHOT
13.10.2 PRODUCT PORTFOLIO
13.10.3 RECENT DEVELOPMENTS
13.11 REDX PHARMA PLC.
13.11.1 COMPANY SNAPSHOT
13.11.2 REVENUE ANALYSIS
13.11.3 PRODUCT PORTFOLIO
13.11.4 RECENT DEVELOPMENTS
13.12 VERONA PHARMA PLC
13.12.1 COMPANY SNAPSHOT
13.12.2 REVENUE ANALYSIS
13.12.3 PRODUCT PORTFOLIO
13.12.4 RECENT DEVELOPMENTS
14 QUESTIONNAIRE
15 RELATED REPORTS
Liste des tableaux
TABLE 1 EUROPE FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 2 EUROPE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 3 EUROPE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 4 EUROPE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2018-2032 (VOLUME)
TABLE 5 EUROPE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2018-2032 (ASP)
TABLE 6 EUROPE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 7 EUROPE ORGAN TRANSPLANT IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 8 EUROPE OXYGEN THERAPY IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 9 EUROPE OTHERS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 10 EUROPE FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 11 EUROPE IDIOPATHIC PULMONARY FIBROSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 12 EUROPE HEPATIC CIRRHOSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 13 EUROPE RENAL FIBROSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 14 EUROPE CUTANEOUS FIBROSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 15 EUROPE OTHERS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 16 EUROPE FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 17 EUROPE HOSPITALS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 18 EUROPE SPECIALTY CLINICS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 19 EUROPE ACADEMIC AND RESEARCH INSTITUTES IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 20 EUROPE OTHER END-USE IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 21 EUROPE FIBROTIC DISEASE TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 22 EUROPE FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 23 EUROPE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 24 EUROPE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 25 EUROPE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 26 EUROPE FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 27 EUROPE FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 28 EUROPE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 29 GERMANY FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 30 GERMANY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 31 GERMANY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 32 GERMANY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 33 GERMANY FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 34 GERMANY FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 35 GERMANY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 36 FRANCE FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 37 FRANCE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 38 FRANCE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 39 FRANCE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 40 FRANCE FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 41 FRANCE FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 42 FRANCE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 43 U.K. FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 44 U.K. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 45 U.K. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 46 U.K. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 47 U.K. FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 48 U.K. FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 49 U.K. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 50 ITALY FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 51 ITALY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 52 ITALY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 53 ITALY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 54 ITALY FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 55 ITALY FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 56 ITALY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 57 SPAIN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 58 SPAIN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 59 SPAIN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 60 SPAIN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 61 SPAIN FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 62 SPAIN FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 63 SPAIN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 64 RUSSIA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 65 RUSSIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 66 RUSSIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 67 RUSSIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 68 RUSSIA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 69 RUSSIA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 70 RUSSIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 71 TURKEY FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 72 TURKEY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 73 TURKEY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 74 TURKEY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 75 TURKEY FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 76 TURKEY FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 77 TURKEY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 78 NETHERLANDS FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 79 NETHERLANDS MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 80 NETHERLANDS MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 81 NETHERLANDS MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 82 NETHERLANDS FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 83 NETHERLANDS FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 84 NETHERLANDS MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 85 SWITZERLAND FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 86 SWITZERLAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 87 SWITZERLAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 88 SWITZERLAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 89 SWITZERLAND FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 90 SWITZERLAND FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 91 SWITZERLAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 92 HUNGARY FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 93 HUNGARY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 94 HUNGARY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 95 HUNGARY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 96 HUNGARY FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 97 HUNGARY FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 98 HUNGARY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 99 LITHUANIA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 100 LITHUANIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 101 LITHUANIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 102 LITHUANIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 103 LITHUANIA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 104 LITHUANIA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 105 LITHUANIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 106 AUSTRIA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 107 AUSTRIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 108 AUSTRIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 109 AUSTRIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 110 AUSTRIA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 111 AUSTRIA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 112 AUSTRIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 113 IRELAND FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 114 IRELAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 115 IRELAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 116 IRELAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 117 IRELAND FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 118 IRELAND FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 119 IRELAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 120 NORWAY FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 121 NORWAY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 122 NORWAY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 123 NORWAY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 124 NORWAY FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 125 NORWAY FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 126 NORWAY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 127 POLAND FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 128 POLAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 129 POLAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 130 POLAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 131 POLAND FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 132 POLAND FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 133 POLAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 134 REST OF EUROPE FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
Liste des figures
FIGURE 1 EUROPE FIBROTIC DISEASE TREATMENT MARKET: SEGMENTATION
FIGURE 2 EUROPE FIBROTIC DISEASE TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE FIBROTIC DISEASE TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 EUROPE FIBROTIC DISEASE TREATMENT MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE FIBROTIC DISEASE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE FIBROTIC DISEASE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE FIBROTIC DISEASE TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 EUROPE FIBROTIC DISEASE TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE FIBROTIC DISEASE TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE FIBROTIC DISEASE TREATMENT MARKET: SEGMENTATION
FIGURE 11 EXECUTIVE SUMMARY
FIGURE 12 STRATEGIC DECISIONS
FIGURE 13 INCREASING PREVALENCE OF CHRONIC DISEASES IS DRIVING THE GROWTH OF THE EUROPE FIBROTIC DISEASE TREATMENT MARKET FROM 2025 TO 2032
FIGURE 14 THE MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE FIBROTIC DISEASE TREATMENT MARKET IN 2025 AND 2032
FIGURE 15 MARKET OVERVIEW
FIGURE 16 EUROPE FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2024
FIGURE 17 EUROPE FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2025-2032 (USD THOUSAND)
FIGURE 18 EUROPE FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, CAGR (2025-2032)
FIGURE 19 EUROPE FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 20 EUROPE FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, 2024
FIGURE 21 EUROPE FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, 2025-2032 (USD THOUSAND)
FIGURE 22 EUROPE FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, CAGR (2025-2032)
FIGURE 23 EUROPE FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 24 EUROPE FIBROTIC DISEASE TREATMENT MARKET: BY END USER, 2024
FIGURE 25 EUROPE FIBROTIC DISEASE TREATMENT MARKET: BY END USER, 2025-2032 (USD THOUSAND)
FIGURE 26 EUROPE FIBROTIC DISEASE TREATMENT MARKET: BY END USER, CAGR (2025-2032)
FIGURE 27 EUROPE FIBROTIC DISEASE TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 28 EUROPE FIBROTIC DISEASE TREATMENT MARKET: SNAPSHOT (2024)
FIGURE 29 EUROPE FIBROTIC DISEASE TREATMENT MARKET: COMPANY SHARE 2024 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.